The work published in Cancer Cell complements previous research
efforts from the CNIO Melanoma Group, which could
lead to the
development of novel
drugs that selectively target the mechanism of cell autodigestion as a potential therapeutic strategy.
ANN ARBOR, Mich. — Sept. 15, 2008 — Assay Designs and the Spinal Muscular Atrophy Foundation (SMAF) are very pleased to announce a collaborative agreement for
development of reagents and assays for SMN (Survival Motor Neuron) protein to expedite
drug discovery and
development efforts for spinal muscular atrophy (SMA), the
leading genetic cause of mortality in infants and toddlers.